Race Oncology Limited
RAC
Rank in Stocks
#16589
Headquartered in Sydney, Australia, Race Oncology Limited is a precision... Headquartered in Sydney, Australia, Race Oncology Limited is a precision oncology company focused on advancing its lead therapeutic, Zantrene. This potent small molecule compound acts as an inhibitor of the fatso/fat mass and obesity associated protein (FTO) and is currently undergoing Phase II/III clinical trials. Zantrene is being investigated for its potential to treat a range of cancers, including melanoma, clear cell renal cell carcinoma, acute myeloid leukaemia, breast cancer, and ovarian cancer. The company maintains an active preclinical research program with the University of Newcastle, focusing on Zantrene, and has also forged a strategic alliance with the University of Wollongong to assess various formulations of the drug. Established in 2011, Race Oncology Limited adopted its current name in July 2016, having previously operated as Coronado Resources Limited.
Share Price
$1.04
Last synced: 2026-11-10
Market Cap
$203.58M
Change (1 day)
0.00%
Change (1 year)
-53.15%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Race Oncology Limited (RAC)
Category
Healthcare
Operating Margin for Race Oncology Limited (RAC)
Operating Margin as of November 2026 TTM: 0.00%
According to Race Oncology Limited's latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of -62.42%.
Operating Margin history for Race Oncology Limited from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | -100.00% |
| 2025 | -62.42% | -85.99% |
| 2024 | -445.48% | 7.50% |
| 2023 | -414.39% | -74.46% |
| 2022 | -1,622.76% | -2.93% |
| 2021 | -1,671.72% | -32.72% |
| 2020 | -2,484.77% | 0.00% |
| 2019 | 0.00% | -100.00% |
| 2018 | -3,717.21% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Race Oncology Limited's operating margin
What was Race Oncology Limited's operating margin in 2025?
In 2025, Race Oncology Limited's operating margin was -62.42%, compared with -445.48% in 2024.
How has Race Oncology Limited's operating margin changed since 2020?
From 2020 to 2025, Race Oncology Limited's operating margin was highest in 2025 (-62.42%) and lowest in 2020 (-2,484.77%).
How does Race Oncology Limited's operating margin compare with similar companies?
Race Oncology Limited's operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.